TB Alliance Statement on New World Health
Organization Rapid Communication on Key Changes to
the Treatment of Drug-Resistant Tuberculosis —
TB Alliance

The TB Alliance (TBA) has issued an official statement on the rapid communication released by the World Health Organization (WHO) Global Tuberculosis Programme in May 2022 which announced new guidelines on the treatment of drug-resistant tuberculosis (DR-TB).  These updated guidelines include alternative shorter novel all-oral regimens such as the 6-month Bedaquiline-Pretomanid-Linezolid (BPaL) treatment regimen.

The Rapid Communication, a prelude to the updated WHO consolidated DR-TB guidelines which is expected in late 2022, aims to inform national TB control programs and other stakeholders of key changes in the treatment of DR-TB and to allow for rapid transition and planning at the country level.   

The details of the TBA statement can be found in this link: https://www.tballiance.org.za/news/who-guidelines-dr-tb